FFM
ELVN icon

Fairmount Funds Management’s Enliven Therapeutics ELVN Stock Holding History

Fairmount Funds Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.2M Hold
1,855,644
– – 6.22% 6
2026
Q1 		$72.7M Sell
1,855,644
-1,855,800
-50% -$51.4M 5.25% 7
2025
Q4 		$57.2M Hold
3,711,444
– – 4.35% 10
2025
Q3 		$76M Hold
3,711,444
– – 6.84% 5
2025
Q2 		$74.5M Buy
3,711,444
+508,646
+16% +$9.63M 9.65% 3
2025
Q1 		$63M Hold
3,202,798
– – 9.78% 4
2024
Q4 		$72.1M Hold
3,202,798
– – 7.16% 6
2024
Q3 		$81.8M Hold
3,202,798
– – 6.63% 5
2024
Q2 		$74.8M Hold
3,202,798
– – 8.46% 5
2024
Q1 		$56.3M Buy
3,202,798
+1,071,429
+50% +$16.4M 6.14% 6
2023
Q4 		$29.5M Hold
2,131,369
– – 3.12% 9
2023
Q3 		$29.1M Buy
2,131,369
+6,744
+0.3% +$114K 3.5% 10
2023
Q2 		$43.4M Buy
2,124,625
+199,687
+10% +$4.04M 6.11% 4
2023
Q1 		$42.2M Buy
1,924,938
+1,767,105
+1,120% +$35.9M 7.25% 5
2022
Q4 		$2.58M Buy
+157,833
New +$2.52M 0.41% 16

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fairmount Funds Management's ELVN Position: Q2 2026 in Review

Fairmount Funds Management held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 1,855,644 shares worth $94.2M. The position accounts for 6.22% of the portfolio, ranked #6.

Fairmount Funds Management first reported a position in ELVN in Q4 2022 and has held it in 15 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Fairmount Funds Management held 1,855,644 shares of Enliven Therapeutics worth $94.2M as of Q2 2026.
  • Fairmount Funds Management left its Enliven Therapeutics share count unchanged in Q2 2026.
  • Enliven Therapeutics made up 6.22% of Fairmount Funds Management's portfolio in Q2 2026, its #6 holding.
  • Fairmount Funds Management first reported a position in Enliven Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.